SAFETY & TOLERABILITY

Dosing

VOCABRIA + REKAMBYS gives your patient 2 months between doses, following initiation[1-4]

Before treatment initiation[1-4]

  • Ensure patients agree to the required 2-monthly dosing schedule, after initiation, and counsel patients about the importance of adherence to scheduled injection visits
  • Set a consistent injection date, the Target Treatment Date, to help keep your patients on track

Every-2-month dosing schedule[1-3]

Following treatment discontinuation[1-3]

It is essential to start alternative ARV therapy no later than 2 months after the final injections (or 1 month if after first initiation injections) in order to minimise the risk of developing viral resistance.

Optional oral lead-in[1-4]

If you would like to assess tolerability, prescribe 2 tablets (1 cabotegravir and 1 rilpivirine tablet) to be taken once daily with a meal for 1 month (at least 28 days).[1-4]

Every-2-month dosing with oral lead-in[1-4]

When given the choice in SOLAR, more participants chose to start with injections than via oral lead-in.[5]

Keep your patients’ injection schedule on track with this treatment planner

The Treatment Planner has been designed to make scheduling appointments for every-2-month VOCABRIA + REKAMBYS easier for you and your team.

Explore our Treatment Planner to help your patients stay on track with VOCABRIA + REKAMBYS

Get started

Computer screen displaying the Treatment Planner page

Which of your patients could benefit from two months between doses?

Managing missed injections

  • If a patient plans to miss a scheduled injection visit by >7 days, oral cabotegravir (30 mg tablet) in combination with rilpivirine (25 mg tablet) once daily may be used for up to 2 consecutive months, to replace 1 missed scheduled injection dose of every-2-month VOCABRIA + REKAMBYS*[1-4]
    • The first dose of oral therapy should be taken 2 months (±7 days) after the last injection dose and continued until the day injection dosing is restarted[1-4]
  • Adherence to scheduled injection visits is important; if a patient missed their Target Treatment Date by >7 days and did not plan for it by taking oral therapy, clinically reassess the patient to determine whether long-acting therapy remains appropriate[1-4]

How to restart injections after oral bridging or missed injection for patients on every-2-month VOCABRIA + REKAMBYS[1-3]

*For oral therapy durations greater than 2 months, an alternative oral regimen is recommended.[1-4]

Share this video to help your patients understand their role in the every-2-month dosing schedule of VOCABRIA + REKAMBYS

Watch video

Discover tools and support for creating treatment plans and administering injections

Explore the overall safety profile of VOCABRIA + REKAMBYS

Contact us for support

ARV=antiretroviral; IM=intramuscular.

References:

  1. VOCABRIA (cabotegravir) 600 mg suspension for injection Summary of Product Characteristics (SmPC).
  2. VOCABRIA (cabotegravir) 30 mg film-coated tablets Summary of Product Characteristics (SmPC).
  3. REKAMBYS (rilpivirine) 900 mg suspension for injection Summary of Product Characteristics (SmPC).
  4. EDURANT (rilpivirine) 25 mg film-coated tablets Summary of Product Characteristics (SmPC).
  5. Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566–e577.

REKAMBYS (rilpivirine long-acting), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned or licensed by the ViiV Healthcare group. ©2025 ViiV Healthcare group of companies or its licensor. All rights reserved.

PM-GB-CBR-WCNT-250008 | March 2026

Prescribing Information

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.